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BACKGROUND: The cancer stem cell (CSC) hypothesis has important clinical implications for cancer therapeutics because of the
proposed role of CSCs in chemoresistance. The aim of this study was to investigate changes in the CSC populations before and after
primary systemic therapy (PST) and their prognostic role in human breast cancer.
METHODS: Paired samples (before and after PST) of breast cancer tissue were obtained from clinical stage II or III patients (n¼92)
undergoing PST with the regimen of doxorubicin plus docetaxel (AD) (n¼50) or doxorubicin plus cyclophosphamide (AC) (n¼42)
and subsequent breast resection. The proportions of putative CSCs with CD44þ/CD24  or aldehyde dehydrogenase 1þ
(ALDH1þ) phenotypes were determined by immunohistochemistry.
RESULTS: A higher proportion of CD44þ/CD24  tumour cells and ALDH1 positivity in pre-chemotherapy tissue was correlated with
higher histologic grade, oestrogen receptor (ER) negativity, high Ki-67 proliferation index and basal-like subtype of breast cancer.
Aldehyde dehydrogenase 1 positivity in pre-chemotherapy biopsy was also associated with a higher rate of pathologic complete
response following PST. In comparisons of putative CSC populations before and after PST, the proportions of CD44þ/CD24  and
ALDH1þ tumour cells were significantly increased after PST. The cases with increased CD44þ/CD24  tumour cell populations
after PST showed high Ki-67 proliferation index in post-chemotherapy specimens and those with increased ALDH1þ tumour cell
population after PST were associated with ER negativity and p53 overexpression. Furthermore, cases showing such an increase had
significantly shorter disease-free survival time than those with no change or a reduced number of CSCs, and the survival difference
was most notable with regard to the changes of ALDH1þ tumour cell population in the patients who received AC regimen.
CONCLUSION: The present study provides the clinical evidence that the putative CSCs in breast cancer are chemoresistant and are
associated with tumour progression, emphasising the need for targeting of CSCs in the breast cancer therapeutics.
British Journal of Cancer (2011) 104, 1730–1738. doi:10.1038/bjc.2011.159 www.bjcancer.com
Published online 10 May 2011
& 2011 Cancer Research UK
Keywords: breast cancer; cancer stem cells; primary systemic therapy; chemoresistance
                                                                       
Primary (neoadjuvant) systemic therapy (PST) is currently
considered the standard care for locally advanced breast cancers
(Buzdar, 2007; Gralow et al, 2008). Primary systemic therapy
permits breast-conserving surgery and treats clinically undetect-
able micrometastatic disease before surgery. In addition, the
degree of response to PST can be used as a prognostic indicator
and pathologic complete response (pCR) is now recognised as an
independent prognostic factor of patients with locally advanced
breast cancer, who had received anthracycline-based or anthracy-
cline- and taxane-based chemotherapy (Wolmark et al, 2001; Bear
et al, 2006; Guarneri et al, 2006; Buzdar, 2007; Symmans et al, 2007;
Chavez-MacGregor et al, 2010). On the other hand, drug resistance
has become the major cause of treatment failure and is largely
responsible for breast cancer mortality (Dean et al, 2005; Kakarala
and Wicha, 2008; Morrison et al, 2008). Overcoming resistance to
chemotherapeutic agents would represent a major advance in the
clinical management of breast cancer.
There is accumulating evidence to support the cancer stem cell
(CSC) hypothesis, which states that cancers are driven by a small
population of stem cells that are capable of self-renewal and give
rise to multipotent progenitor cells, and eventually, differentiate
into all cell types within the tumour (Smalley and Ashworth, 2003;
Clarke et al, 2006; Campbell and Polyak, 2007; Visvader and
Lindeman, 2008; Nakshatri et al, 2009). Cancer stem cells may
originate by malignant transformation of normal stem cells that
have accumulated genetic and epigenetic modifications over time
(Smalley and Ashworth, 2003; Dean et al, 2005; Visvader and
Lindeman, 2008). Alternatively, they may arise from restricted
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sprogenitors of more differentiated cells that have acquired self-
renewing capacity through multiple genetic and epigenetic
alterations (Smalley and Ashworth, 2003; Dean et al, 2005;
Visvader and Lindeman, 2008).
Cancer stem cells were first identified in acute myeloid
leukaemia (Lapidot et al, 1994), and recently, have also been
documented in various solid tumours, including those of breast
(Al-Hajj et al, 2003), brain (Singh et al, 2004), lung (Kim et al,
2005), colon (O’Brien et al, 2007), prostate (Collins et al, 2005) and
pancreas (Li et al, 2007). In the case of breast tumours, Al-Hajj
et al (2003) were the first to isolate a highly tumourigenic
subpopulation of tumour cells with CD44
þ/CD24
 /low/Lineage
 
phenotype. Subsequently, Ginestier et al (2007) presented evidence
that aldehyde dehydrogenase 1 (ALDH1) is a marker of stem/
progenitor cells of the normal and malignant human breast. They
demonstrated the tumourigenicity of ALDH1-positive cells by
injection of ALDEFLUOR-positive population into NOD/SCID
mice and detected ALDH1 expressing tumour cells in breast
carcinoma tissue by immunohistochemistry. However, it is also
known that none of these CSC markers is expressed exclusively by
stem cells, and a considerable number of cells that express these
markers are not stem cells, resulting in phenotypic heterogeneity
within putative CSC populations (Clarke et al, 2006; Visvader and
Lindeman, 2008).
The CSC hypothesis has important clinical implications for
cancer therapeutics because of the suggested role of CSCs in
chemoresistance (Kakarala and Wicha, 2008). There is increasing
evidence that CSCs are naturally resistant to chemotherapy on
account of their quiescence, more efficient DNA repair, resistance
to apoptosis and expression of drug-resistance proteins, such as
ATP-binding cassette transporters (ABCG2 and ABCG5) and
multidrug-resistance protein 1 transporters (Dean et al, 2005).
If this is correct, a small population of chemoresistant CSCs may
resist killing by conventional chemotherapy, whereas majority of
tumour cells, which are differentiated cells that lack ‘stemness’,
may be killed. The tumour could, therefore, regrow after
chemotherapy because of the capacity for self-renewal of these
CSCs. However, there have been few reports of chemoresistance of
CSCs in human breast tissue (Li et al, 2008; Tanei et al, 2009),
although several in vitro studies have indicated it (Liu et al, 2006;
Ghods et al, 2007; Yu et al, 2007; Fillmore and Kuperwasser, 2008).
The aim of this study was to investigate changes in CSC
populations before and after PST and their prognostic role in
human breast cancer. We determined the proportions of putative
CSCs with CD44þ/CD24  or ALDH1þ phenotypes using
immunohistochemistry in pre- and post-chemotherapy breast
cancer tissue, and analysed the association between the changes of
putative CSC population after PST and clinicopathologic para-
meters, including patients’ survival.
PATIENTS AND METHODS
Patients and specimens
Ninety-two patients with clinical stage II or III breast cancer (by
AJCC 7th), who received surgical resection after PST in Seoul
National University Bundang Hospital from May 2003 to February
2009 were enrolled. All patients were diagnosed to have invasive
breast carcinoma by core needle biopsy, and were started on PST.
Fifty patients were treated with doxorubicin plus docetaxel (AD)
regimen containing 50mgm
–2 doxorubicin i.v. on day 1 and
75mgm
–2 docetaxel i.v. on day 1 every 3 weeks for three to six
cycles (mean, five cycles). Forty-two patients received doxorubicin
plus cyclophosphamide (AC) regimen containing 60mgm
–2
doxorubicin i.v. on day 1 and 600mgm
–2 cyclophosphamide i.v.
on day 1 every 3 weeks for four cycles. Formalin-fixed and
paraffin-embedded paired tissue samples of pre-chemotherapy
biopsy and post-chemotherapy surgical resection were collected
from each patient. None had received radiation therapy preopera-
tively. All were female, with a median age of 46 (range, 28–70).
Clinicopathologic information was obtained by reviewing medical
records, pathology reports and H&E-stained sections. The follow-
ing histopathologic variables were determined: histologic subtype,
Bloom-Richardson histologic grade, T stage, N stage, oestrogen
receptor (ER), progesterone receptor (PR), HER2 status, Ki-67
proliferation index and P53 expression. Pathological complete
response following PST was defined as complete disappearance of
all invasive cancer or only residual ductal carcinoma in situ. The
duration of disease-free survival (DFS) was defined as the time
between the start of PST and first recurrence/metastasis or death.
All cases were independently reviewed by two breast pathologists
(SYP and HEL). This study was approved by the Institutional
Review Board of Seoul National University Bundang Hospital
(protocol # B-1008-110-301), waiving the requirement for informed
consent for the study.
Immunohistochemical staining
Formalin-fixed and paraffin-embedded sections were dewaxed in
xylene, rehydrated through graded alcohol and placed in an
endogenous peroxide block for 15min. Antigen retrieval was
carried out by microwave in 10mM citrate buffer. Nonspecific
staining was blocked by treating sections with 10% goat serum in
phosphate-buffered saline (pH 6.0) for 10min. Immunohisto-
chemical staining was carried out in a DAKO Autostainer Plus
(Dako, Glostrup, Denmark) using an LSAB detection kit (Dako).
The following primary antibodies were used: CD44 (1:200; clone
156-3C11; Neomarkers, Fremont, CA, USA), CD24 (1:100; clone
SN3b; Neomarkers), ALDH1 (1:100; clone 44; BD Biosciences,
Franklin Lakes, NJ, USA), cytokeratin 5/6 (CK5/6) (1:50; clone
D5/16 B4; Dako) and epidermal growth factor receptor (EGFR)
(EGFR pharmDx, Dako). The proportions of each antibody-
positive tumour cells were counted semiquantitatively.
Double immunohistochemical staining for CD44 and CD24
Double immunostaining with antibodies to detect CD44 and CD24
was performed with EnVision G|2 Doublestain System Rabbit/
Mouse (diaminobenzidineþ (DABþ)/Permanent Red) (Dako,
Carpinteria, CA, USA) according to the manufacturer’s instruc-
tions. CD44 was detected with DAB and CD24 with Permanent
Red. We confirmed the accuracy of the double immunostaining by
comparing it with single immunostaining for CD44 and CD24,
separately. The proportions of CD44þ/CD24  tumour cells was
counted semiquantitatively and scored in 5% increments.
Breast cancer subtypes
Although intrinsic subtypes of breast cancer were originally
defined by gene expression profiling using DNA microarrays,
most archival formalin-fixed paraffin-embedded samples are not
amenable to cDNA microarray and subsequent studies revealed
that subtypes can be accurately determined using immunohisto-
chemical as a surrogate for molecular classification (Nielsen et al,
2004; Carey et al, 2006). Thus, breast cancer subtypes were defined
as previously with minor modifications (Nielsen et al, 2004; Carey
et al, 2006). Subtype definitions in this study were as follows:
luminal A (ERþ and/or PRþ, HER2 ), luminal B (ERþ and/or
PRþ, HER2þ), HER2þ (ER ,P R  , HER2þ), basal-like (ER ,
PR , HER2 , CK5/6þ and/or EGFRþ) and unclassified
(negative for all markers).
With regard to immunostaining for ER and PR, cases with 10%
or more positive staining were grouped as positive. Expression of
EGFR and HER2 was scored as follows: 0, no staining; 1þ, weak
and incomplete membranous staining in X10% of the tumour
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scells; 2þ, weak to moderate, complete membranous staining in
X10% of the tumour cells and 3þ, strong, complete membranous
staining in X30% of the tumour cells. Any positive staining was
regarded as positive for EGFR, and 3þ on immunohistochemistry
or presence of gene amplification on fluorescence in situ
hybridisation was considered HER2 positive. For CK5/6, cases
with any degree of positive staining were grouped as positive.
Statistical analyses
Non-continuous variables were compared using the w
2-test or
Fisher’s exact (two-sided) test and continuous variables using the
Mann–Whitney U-test. Univariate and multivariate logistic
regression models were used to identify predictive factors of
pCR following PST. Changes of the CD44þ/CD24  and ALDH1þ
tumour cell populations before vs after PST were evaluated by
Wilcoxon’s signed-rank test. Survival curves were estimated using
the Kaplan–Meier product-limit method, and the significances of
differences between survival curves were determined using the log-
rank test. The covariates, which were statistically significant in the
univariate analysis, were then included in the multivariate analysis
using Cox proportional hazards regression model; the hazard ratio
(HR) and its 95% confidence interval (CI) were assessed for each
factor. All statistical analyses were conducted using SPSS statistics
17.0 (SPSS Inc., Chicago, IL, USA), and P-values of p0.05 were
considered statistically significant.
RESULTS
Detection of CD44þ/CD24  and ALDH1þ tumour cells
in pre-chemotherapy biopsy tissue
In 92 pre-chemotherapy biopsy tissues, median values of CD44þ/
CD24  and ALDH1þ tumour cell proportions were 5% (range,
0–95%) and 0% (0–80%), respectively. When ALDH1 immuno-
staining was classified into negative (ALDH1þ tumour cells o5%),
1þ (X5%, o10%,), 2þ (X10%, o50%) and 3þ (450%)
groups, there were 80 (87.0%), 3 (3.3%), 8 (8.7%) and 1 (1.1%)
cases assigned to the negative, 1þ,2 þ and 3þ groups,
respectively. We further classified the cases into negative (o5%;
n¼80) and positive (X5%; n¼12) groups for ALDH1 and found
that the ALDH1-positive group contained a higher proportion of
CD44þ/CD24  tumour cells than the ALDH1-negative group
(median (interquartile range), 45% (20–70%) vs 5% (1–30%);
P¼0.003).
Association between CD44þ/CD24  and ALDH1þ
tumour cell populations in pre-chemotherapy tissue
and clinicopathologic characteristics
We analysed the relationship between CD44/CD24 and ALDH1
expression status in pre-chemotherapy tissue and various clinico-
pathologic parameters. A higher proportion of CD44þ/CD24 
tumour cells and ALDH1 positivity was associated with higher
histologic grade (P¼0.002 and P¼0.007, respectively) and ER
negativity of tumour (Po0.001 and Po0.001, respectively).
Neither clinical T nor clinical node stage was related to CD44/
CD24 or ALDH1 status. The differences in CD44þ/CD24  tumour
cell proportions and ALDH1 positivity between the subtypes of
breast cancer were statistically significant. Specifically, the basal-
like subtype had the highest proportion of CD44þ/CD24 
tumour cells and the highest frequency of ALDH1 positivity
among the subtypes. In addition, Ki-67 proliferation index was
positively correlated with ALDH1 status (P¼0.020) (Table 1).
CD44/CD24 and ALDH1 expression status in pre-chemotherapy
specimens was not associated with DFS (data not shown).
CD44þ/CD24  and ALDH1þ tumour cell population as a
predictive factor of pCR
Thirteen (13.7%) of the 92 patients, that is 5 (10.0%) of 50 patients
who were treated with AD regimen and 8 (19.0%) of 42 patients
who received AC regimen, achieved a pCR after PST and there was
no statistical difference in pCR rate according to PST regimen.
Aldehyde dehydrogenase 1 positivity of pre-chemotherapy tissue
was significantly correlated with a higher rate of pCR after PST
(10 vs 42%; P¼0.003; Figure 1B). This association was also found
according to PST regimen (AD or AC regimen), although a
statistical significance was reached only for AD regimen
(P¼0.024) (Figures 1D and F). The pCR group also showed a
tendency to have a higher proportion of CD44þ/CD24  tumour
cells than the non-pCR group not showing pCR in total patients
(P¼0.262) and in the subgroup receiving AC regimen (P¼0.130)
(Figures 1A, C and E).
To determine whether CD44þ/CD24  tumour cell proportion
and ALDH1 positivity were predictive factors of pCR, we
Table 1 Association between pre-chemotherapy CD44+/CD24 
tumour cell proportions and ALDH1 positivity and clinicopathologic
characteristics of the tumours
CD44+/CD24 
tumour cell
population
ALDH1
expression
of tumour cells
Characteristics
Median
(IQR) (%) P-value
a
Negative
(no. (%))
Positive
(no. (%)) P-value
b
cT stage 0.053 0.159
T1 (2) and T2 (47) 5 (1–42.5) 40 (50) 9 (75)
T3 (30) 5 (1–22.5) 28 (35) 2 (17)
T4 (13) 45 (5–77.5) 12 (15) 1 (8)
cN stage 0.265 1.000
N0 (12) 25 (1–63.8) 11 (14) 1 (8)
N1–3 (80) 5 (1–40) 69 (86) 11 (92)
cTNM stage 0.288 0.538
II (41) 5 (1–35) 37 (46) 4 (33)
III (51) 10 (1–45) 43 (54) 8 (67)
Histologic grade 0.002 0.007
Grade I (7) 5 (1–50) 7 (9) 0(0)
Grade II (45) 5 (0–15) 43 (56) 2 (17)
Grade III (37) 20 (5–65) 27 (35) 10 (83)
Oestrogen receptor o0.001 o0.001
Negative (35) 20 (5–65) 24 (30) 11 (92)
Positive (57) 5 (0–20) 56 (70) 1 (8)
HER2 0.134 0.746
Negative (63) 10 (1–55) 54 (68) 9 (75)
Positive (29) 5 (1–15) 26 (32) 3 (25)
Breast cancer subtype 0.001 o0.001
Luminal A (40) 5 (0–35) 40 (50) 0 (0)
Luminal B (16) 3.5 (0–15) 15 (19) 1 (8)
HER2+ (13) 10 (1.5–20) 11 (14) 2 (17)
Basal-like (23) 45 (15–70) 14 (17) 9 (75)
Ki-67 labelling index 0.064 0.020
p20% (44) 5 (0–35) 42 (53) 2 (17)
420% (48) 12.5 (2–52.5) 38 (47) 10 (83)
P53 staining 0.124 0.856
Negative (67) 10 (1–45) 58 (73) 9 (75)
Positive (25) 2 (1–15) 22 (27) 3 (25)
Abbreviations: ALDH1¼aldehyde dehydrogenase 1; cN¼clinical node; cT¼clinical
tumor; cTNM¼clinical tumor-node-metastasis; HER2¼human epidermal growth
factor receptor 2; IQR¼interquartile range.
aMann–Whitney U-test or Kruskal–Wallis
test.
bw
2 or Fisher’s exact test. IQR (25–75%).
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sperformed logistic regression analyses. In univariate analysis, ALDH1
positivity and high histologic grade were found to be significantly
associated with pCR (P¼0.007 and 0.037, respectively). However, in
multivariate analysis, they did not remain as independent predictive
factors. CD44þ/CD24  tumour cell proportion was not a signifi-
cant predictive factor of pCR (Table 2).
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Figure 1 Association of CD44þ/CD24  and ALDH1þ status with pathologic complete responses (pCR) following primary systemic therapy in total
patients (A and B) and in the subgroups by the primary systemic therapy regimen (C–F). The group showing pCR tended to have a higher proportion of
CD44þ/CD24  tumour cells than the non-pCR group in total patients (A) and in the subgroup treated with AC regimen (E). The ALDH1 positive group
had a significantly higher likelihood of pCR than the ALDH-1-negative group in total (B). This association was also found irrespective of primary systemic
therapy regimen (AD or AC regimen), although a statistical significance was reached only for AD regimen (D and F). AD¼doxorubicin plus docetaxel;
AC¼doxorubicin plus cyclophosphamide.
Table 2 Univariate and multivariate logistic regression models for predictors of pCR following PST
Variables Odds ratio 95% CI P-value
Univariate analysis
CD44+/CD24  tumour cell proportion (continuous) 1.014 0.996–1.034 0.135
ALDH1 positivity (negative vs positive) 6.429 1.649–25.056 0.007
Histologic grade (grades I, II vs III) 4.295 1.087–13.689 0.037
Oestrogen receptor (ER+ vs ER ) 2.125 0.650–6.942 0.212
Breast cancer subtype (non basal-like vs basal-like) 3.126 0.927–10.539 0.066
cT stage (cT3, 4 vs cT1, 2) 3.419 0.879–13.367 0.077
cN stage (cN1–3 vs cN0) 1.255 0.242–6.507 0.787
PST regimen (AD vs AC) 2.118 0.636–7.051 0.221
Multivariate analysis
ALDH1 positivity (negative vs positive) 4.150 0.970–17.765 0.055
Histologic grade (grades I, II vs III) 2.625 0.670–10.276 0.166
Abbreviations: AC¼doxorubicin plus cyclophosphamide; AD¼doxorubicin plus docetaxel; ALDH1¼aldehyde dehydrogenase 1; CI¼confidence interval; cN¼clinical node;
cT¼clinical tumor; pCR¼pathologic complete response; PST¼primary systemic therapy.
Breast cancer stem cell changes after chemotherapy
HE Lee et al
1733
British Journal of Cancer (2011) 104(11), 1730–1738 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sChanges of CD44þ/CD24  and ALDH1þ tumour cell
populations before and after PST and their relationships
with DFS
We assessed changes of CD44þ/CD24  and ALDH1þ tumour
cell populations before and after PST in the 79 patients who did
not achieve pCR. Both CD44þ/CD24  tumour cell proportions
and grades of ALDH1þ tumour cells significantly increased after
PST (P¼0.013 and P¼0.018, respectively) (Figures 2A, B and 3).
Within the subgroup receiving AD regimen, CD44þ/CD24 
tumour cell proportions also increased significantly (P¼0.017)
and the grades of ALDH1þ tumour cells had a tendency to
increase after PST (P¼0.098). In the subgroup treated with AC
regimen, grades of ALDH1þ tumour cells increased after PST
with a marginal significance (P¼0.059) (Figures 2C–F). Also, we
investigated whether the changes of putative CSC population after
PST varied according to breast cancer subtype. There were
increasing trends of the putative CSC populations after PST
regardless of the breast cancer subtype, and especially, grades of
ALDH1þ tumour cells were significantly increased after PST in
HER2þ subtype (P¼0.034) (Table 3).
We analysed the association between the changes of CD44þ/
CD24  and ALDH1þ tumour cell population and clinicopatho-
logic characteristics of tumour after PST. The cases with increased
CD44þ/CD24  tumour cell populations after PST showed high
Ki-67 proliferation index in post-chemotherapy specimens
(P¼0.038) and tended to show high post-neoadjuvant therapy
pathologic T (ypT) stage (P¼0.091) and ER negativity (P¼0.067).
The cases with increased ALDH1þ tumour cell population after
PST were associated with ER negativity (P¼0.017) and p53
overexpression (P¼0.030) (Table 4).
We also investigated the relationships of the changes of
CD44þ/CD24  and ALDH1þ tumour cell population after PST
with DFS. At the time of the analysis, the median follow-up was 3
years (range, 1–7 years). There were four (4%) loco-regional
recurrences as first events and seven (8%) distant metastases. In
Kaplan–Meier survival analyses, the patients with increased
CD44þ/CD24  and ALDH1þ tumour cell populations had a
significantly shorter DFS times than the remaining patients
(P¼0.043 and 0.041, respectively) (Figures 4A and B). Subgroup
analyses by the PST regimen revealed that the survival difference
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Figure 2 Changes of putative CSC populations after primary systemic therapy (PST) in the cases not achieving pathologic complete response. CD44þ/
CD24  tumour cell proportions (A) and ALDH1þ tumour cell grades (B) increased significantly after PST in total. Within the subgroup receiving AD
regimen (C and D), CD44þ/CD24  tumour cell proportions increased significantly (C) and the grades of ALDH1þ tumour cells showed a tendency to
increase after PST (D). In the subgroup treated with AC regimen (E and F), only grades of ALDH1þ tumour cells increased after PST with a marginal
significance (F). AD¼doxorubicin plus docetaxel; AC¼doxorubicin plus cyclophosphamide.
Breast cancer stem cell changes after chemotherapy
HE Lee et al
1734
British Journal of Cancer (2011) 104(11), 1730–1738 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
swas much greater in the patients receiving AC regimen between the
group with increased ALDHþ tumour cell population after PST
and the remaining group (Po0.001). On the other hand, there was
no survival difference between the two groups in patients treated
with AD regimen. With regard to the changes of CD44þ/CD24 
tumour cell populations, the patients with the increase of CD44þ/
CD24  tumour cell populations tended to have shorter DFS times
than the remaining patients irrespective of PST regimen, although
they were not statistically significant (Figures 4C–F). In multivariate
analysis, ypT stage (ypT0-2 vs ypT3-4; HR, 4.82; 95% CI: 1.28–18.18;
P¼0.020) was identified as an independent predictor for DFS.
However, the changes of CD44þ/CD24  and ALDH1þ tumour
cell populations did not remain as independent prognostic factors.
DISCUSSION
The present study showed that putative CSCs identified by CD44/
CD24 and ALDH1 immunohistochemistry significantly increased
after PST in human breast cancer tissue. In addition, the cases with
increased CD44þ/CD24  tumour cell populations after PST were
found to have high Ki-67 proliferation index in post-chemotherapy
specimens. More importantly, we report for the first time that the
patients in whom the putative CSC population increased after PST
had significantly shorter DFS times than patients in whom the
putative CSC population were not changed or decreased.
Furthermore, in the subgroup receiving AC regimen, the DFS
time was much shorter in patients with increased ALDHþ tumour
cell population after PST than in the remaining patients. These
findings indicate that putative CSCs with CD44þ/CD24  or
ALDH1þ phenotypes have an important role in chemoresistance
to conventional AD and AC therapy and in disease progression.
There are several previous reports that CSCs contributes to
chemoresistance in cancer therapeutics. However, most of them
are in vitro studies (Liu et al, 2006; Ghods et al, 2007; Yu et al,
2007; Fillmore and Kuperwasser, 2008), and there are few reports
showing an association between CSCs and chemoresistance in
human breast cancer tissue. Some previous comparative studies
using paired human breast cancer tissue obtained before and after
chemotherapy found that CD44þ/CD24  (Li et al, 2008) or
ALDH1þ (Tanei et al, 2009) tumour cells increased significantly
after chemotherapy, which is in agreement with our results.
However, other workers detected no significant enrichment of
ALDH1þ tumour cells (Resetkova et al, 2010) or even a reduction of
CD44þ/CD24  tumour cells (Aulmann et al, 2010) after PST. The
contradictory results could be explained as follows. First, the PST
regimens and cycles differed in the various studies, and there may be
treatment-specific influences on outcomes. Alternatively, differences
in immunostaining methods and scoring protocols may have
contributed to the discrepancies. In vivo studies using larger cohorts
and more standardised methods will be required to settle the matter.
We characterised the putative CSC-rich breast cancer by
assessing the relationship between CD44/CD24 or ALDH1 expres-
sion in pre-chemotherapy tissue and clinicopathologic parameters.
In the current study, most of CD44þ/CD24  or ALDH1þ
cell-rich tumours belonged to the basal-like subtype, which
accords with the several previous reports pointing to a relation
between CSCs and the basal-like subtype (Honeth et al, 2008;
Morimoto et al, 2009; Nalwoga et al, 2010; Park et al, 2010). These
tumours displayed features of aggressive tumours, such as high
Figure 3 A representative example of the changes in putative CSC populations after primary systemic therapy. Both CD44þ/CD24  (A) and
ALDH1þ (B) tumour cells were increased after PST in this case. An arrow head, a CD44þ/CD24þ cell; arrows, CD44þ/CD24  cells (original
magnifications,  400).
Table 3 Changes of putative CSC population before and after PST
according to the breast cancer subtype in the cases not achieving pCR
Breast
cancer
subtypes
CD44+/CD24 
tumour cell proportion
(median (IQR), %)
a
Changes of ALDH1
grade (case no. with
increase/no change/
decrease of ALDH1
grade after PST)
a
Before PST After PST
Luminal A (n¼38) 5 (0–35) 6.5 (0–47.5) 2/36/0
Luminal B (n¼13) 3.5 (0–15) 0 (0–22.5) 1/12/0
HER2+ (n¼11) 10 (1.5–20) 40 (0.5–70) 5/6/0
b
Basal-like (n¼17) 45 (15–70) 55 (20–80) 3/13/1
Abbreviations: ALDH1¼aldehyde dehydrogenase 1; CSC¼cancer stem cell;
HER2¼human epidermal growth factor receptor 2; IQR¼interquartile range;
pCR¼pathologic complete response; PST¼primary systemic therapy.
aWilcoxon’s
signed-rank test;
bP¼0.034.
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shistologic grade and high Ki-67 proliferation index, which are also
characteristics of basal-like breast cancers as well.
With regard to the effect of CSC population size on patients’
survival, there have been contradictory results. Whereas some
studies failed to find a relationships between them (Abraham et al,
2005; Resetkova et al, 2010), others showed an inverse correlation
(Ginestier et al, 2007; Morimoto et al, 2009; Charafe-Jauffret et al,
2010). In the present study, we found that increased CD44þ/
CD24  and ALDH1þ tumour cell populations in post-che-
motherapy specimen were prognostic factors for DFS, despite the
fact that the size of the CD44þ/CD24  or ALDH1þ tumour cell
populations in pre-chemotherapy biopsy were not related to
patients’ survival. The CD44þ/CD24  and ALDH1þ tumour
cells in post-chemotherapy specimens may constitute more
specific chemoresistant CSC populations than those in pre-
chemotherapy specimens, and thus may have greater clinical
significance. However, we cannot rule out the possibility that
differentiated tumour cells acquire the CSC phenotype after
chemotherapy due to selection pressure. In respect to breast
cancer subtypes on patients’ survival after PST, triple negative or
basal-like breast cancers have been reported to show worse
survival due to high relapse among those with residual disease
after PST, despite higher chemosensitivity to conventional
anthracyclin-based chemotherapy (so-called ‘triple-negative para-
dox’) (Carey et al, 2007; Bhargava et al, 2010). As basal-like
tumours are enriched with CD44þ/CD24  or ALDH1þ tumour
cell population, as shown in this study, one may expect that the
cases with increased CSC population after PST were mostly
chemoresistant basal-like subtype and thus, show wore prognosis.
However, there were no differences in the number of cases with
increased CSC populations according to subtype. And even if
patients’ survival was analysed only in the non-pCR group, we can
find the tendency to have worse survival in cases with increased
CD44þ/CD24  or ALDH1þ tumour cell populations (P¼0.127,
0.087, respectively; data not shown).
Although this study revealed prognostic significance of in-
creased putative CSC population after PST in total, we failed to
show its prognostic significance in the subgroup analyses
according to PST regimen except for the changes of ALDH1þ
tumour cell population in the subgroup receiving AC regimen.
However, as our study was limited to a short follow-up period
and a small number of cases, more extensive studies are needed
to confirm the prognostic value of the CSC populations in
post-chemotherapy specimens, especially, according to different
chemotherapeutic regimens.
We found that ALDH1 positivity was significantly associated
with the likelihood of pCR in breast cancer. Also, the group of
patients showing pCR had a higher proportion of CD44þ/CD24 
tumour cells than those not showing pCR, although the difference
was not statistically significant. These observations would seem to
indicate that CSCs are chemosensitive, which appears to contradict
our suggestion that they have a key role in chemoresistance.
However, if cellular heterogeneity exist within the CSC populations
detected by the putative breast CSC markers, all the CD44þ/
CD24  and ALDH1þ tumour cells would not necessarily be CSCs.
Accordingly, those that were easily killed by PST in this study are
not likely to be CSCs per se, but rather transit amplifying cells.
Other important points to note are that breast cancers that have
high histologic grades, are ER negative and have high Ki-67
proliferation indices, are prone to achieve pCR following PST, as
demonstrated in many previous studies (Ellis et al, 1998; Chang
et al, 1999; Rouzier et al, 2005; Carey et al, 2007) and that
ER-negative cancers, especially basal-like breast cancers, are
enriched in CSCs (Honeth et al, 2008; Morimoto et al, 2009;
Nalwoga et al, 2010; Park et al, 2010). Taken together, the reason
why tumours with high CD44þ/CD24  and ALDH1þ cell
populations tend to achieve pCR may be related to their possession
of pathologic features predictive of pCR (high histologic grade, ER
negativity and high Ki-67 proliferation index, etc.), rather than
with their stem cell properties.
The CSC hypothesis has important clinical implications for early
detection, prevention and treatment of breast cancer. On the basis of
that hypothesis, clinical trials are now being initiated that use drugs
targeting CSCs or CSC-regulatory molecules, such as g secretase
inhibitors that are able to inhibit Notch signalling and inhibitors of
hedgehog signalling (Kakarala and Wicha, 2008). Our observation of
Table 4 Association between the changes of putative CSC population after PST and clinicopathologic characteristics of the tumours in the post-
chemotherapy specimens
CD44+/CD24  tumour cell proportion ALDH1 grade
Characteristics
No change or
decrease (no. (%))
Increase
(no. (%)) P-value
a
No change or
decrease (no. (%))
Increase
(no. (%)) P-value
a
ypT stage 0.091 0.185
T0–2 (79) 50 (91) 29 (78) 71 (88) 8 (73)
T3–4 (13) 5 (9) 8 (22) 10 (12) 3 (27)
ypN stage 0.267 0.745
N0 (31) 21 (38) 10 (27) 28 (35) 3 (27)
N1–3 (61) 34 (62) 27 (73) 53 (65) 8 (73)
Oestrogen receptor
b 0.067 0.017
Negative (30) 12 (29) 18 (49) 22 (32) 8 (73)
Positive (49) 30 (71) 19 (51) 46 (68) 3 (27)
HER2
c 0.933 0.150
Negative (58) 31 (74) 27 (73) 52 (77) 6 (55)
Positive (21) 11 (26) 10 (27) 16 (23) 5 (45)
Ki-67 labelling index 0.038 0.311
p20% (54) 33 (79) 21 (57) 48 (71) 6 (55)
420% (25) 9 (21) 16 (43) 20 (29) 5 (45)
P53 staining 0.575 0.030
Negative (64) 35 (83) 29 (78) 58 (85) 6 (55)
Positive (15) 7 (17) 8 (22) 10 (15) 5 (45)
Abbreviations: ALDH1¼aldehyde dehydrogenase 1; CSC¼cancer stem cell; HER2¼human epidermal growth factor receptor 2; PST¼primary systemic therapy; ypT¼post-
neoadjuvant therapy pathologic tumor; ypN¼post-neoadjuvant therapy pathologic node.
aw
2 or Fisher’s exact test.
bOestrogen receptor status was changed from positive to
negative after PST in two cases.
cHER2 status was converted from negative to positive after PST in a case.
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sthe association between CSCs and chemoresistance in the present
study underlines the importance of targeting therapy to CSCs.
In conclusion, the present study indicates the chemoresistant
property of putative CSCs to the conventional anthracyclin-based
chemotherapy and their role in disease progression by demon-
strating an increase in the proportion of CSCs after PST and their
association with reduced DFS. These findings emphasise the need
to target CSCs in breast cancer treatment. We also suggest that the
breast CSC population detected by CD44/CD24 or ALDH1
expression is heterogeneous and hence that validation of these
CSC markers and the development of the more definitive markers
would be important.
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